Abstract / Summary
Atrial fibrillation (AF) detection following ischemic stroke is critical to guide management. Echocardiography (echo) is commonly performed poststroke and may help identify candidates for prolonged rhythm monitoring. The PER DIEM trial randomized poststroke patients without known AF to 12-months of implantable loop recorder (ILR) monitoring versus 30-days of external rhythm monitoring and demonstrated higher AF detection rates using ILR. This substudy of the PER DIEM trial investigated the association between baseline echo parameters and poststroke AF detection. PER DIEM trial participants with complete transthoracic echo performed at the time of ischemic stroke were included. Demographic, clinical, and echocardiographic parameters were compared between those with and without AF. Nineteen (12.4%) of the 153 patients included had poststroke AF. AF patients were significantly older and had higher CHA2DS2-VASc scores. Patients with AF had higher left atrial volume index (LAVI), lower absolute left ventricular global longitudinal strain (LV GLS) and lower contractile LA strain compared to those without AF. Univariate analysis showed that a higher LAVI (OR 1.30 per 5 mL/m2 increase, 95%CI 1.03-1.64, p = 0.025) and lower absolute LV GLS (OR 2.73 per 5% decrease, 95%CI 1.37-6.04, p = 0.007) were significantly associated with poststroke AF, with optimal cutoff values of 32.12 mL/m2 and 15.5%, respectively. In patients with ischemic stroke, LAVI and LV GLS were significantly associated with subsequent AF detection. These findings may help risk stratify AF monitoring strategies for postischemic stroke management.
Primary Source
Echocardiography (Mount Kisco, N.Y.)
Ask Prognia AI
Have questions about this randomised trial?
Prognia AI can search this source alongside 35M+ PubMed papers and current ESC, AHA, NICE, and ADA guidelines to give you a fully cited clinical answer.
Related Clinical Guidelines
Related Blog Posts
ESC 2023 Heart Failure Guidelines: What Every Cardiologist Needs to Know
The 2023 focused update to the ESC Heart Failure Guidelines introduced key changes to SGLT2 inhibitor recommendations, HFmrEF management, and device therapy thresholds. Here is a practical summary.
CHADS₂-VASc in Practice: When to Start Anticoagulation in AF
A practical walkthrough of the CHADS₂-VASc scoring system, its ESC guideline thresholds, and how to use it alongside HAS-BLED to counsel patients with atrial fibrillation.